Covid: the US to roll-out second vaccine from Moderna after USFDA approvals

Covid: After Pfizer and BioNTech Vaccine, the second vaccine is ready to use and approached USFDA for emergency use of authorization. The agency is likely to authorize the Moderna vaccine and allowing to ship millions of doses across the world. On the other side, the US reported a spike in covid cases and the death toll crossed 3 lakhs earlier this week.

On Thursday, the advisory panel voted 20-0 with one non-indulgence in it. The Moderna vaccine exceeds more risk to those people aged 18 and over. Whereas the same panel approved the Pfizer/BioNTech Vaccine last week, which leads to emergency use of authorization.

After the advisory panel’s recommendations, the USFDA Commissioner Stephen Hahn said the panel members informed about the Moderna vaccine safety and issuance of emergency use of authorization. He also mentioned that the Moderna vaccine is almost 95% effective.

On the other side, the Moderna Vaccine is placed at -20C for shipping. While the Pfizer Vaccine requires almost -75C for shipping, it is more difficult for the logistic companies. Both vaccines require a second dose, which comes after 28 days after the first dose.

However, the companies manufactured plants located in Cambridge, Massachusetts. After USFDA approvals, the company manufactures millions of doses in their facility. Whereas the Pfizer/BioNTech Vaccine is manufacturing at several places across the world, including Germany and Belgium.

Besides, the Moderna company made an agreement to roll-out almost 56 million doses to the Canada Government. While the UK government pre-ordered almost 7 million doses from the company. The European Union made an agreement in last month for 80 million doses. On the other side, Japan ordered 50 million doses, South Korea ordered 20 million, Switzerland ordered 7.50 million respectively.